Zevra Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
1.5%projected annual EPS growth
Analyst Coverage
9analysts covering
FY Revenue (est.)
$152.2Mnext fiscal year
FY EPS (est.)
$1.14next fiscal year
Monitoring Framework
Key Performance Indicators
MIPLYFFA Net Revenue Quarterly24.6M
Global Expanded Access Program (EAP) Net Reimbursements Quarterly10.2M
MIPLYFFA Prescription Enrollment Forms (Cumulative) Quarterly170.0
Global EAP Patient Enrollment Quarterly122.0
Watch Items
- European Medicines Agency (EMA) Marketing Authorisation Application (MAA) review for arimoclomolTrigger: CHMP opinion or final EMA decisionAction: Assess potential European market size, launch timeline, and update valuation models upon regulatory decision.
- Strategic alternatives evaluation for OLPRUVATrigger: Announcement of divestiture, licensing, or complete discontinuationAction: Evaluate impact on operating expenses and cash runway from scaling back or divesting the UCD franchise.
- Clinical development progress of celiprolol for vascular Ehlers-Danlos syndrome (vEDS)Trigger: Phase 3 trial data readouts or enrollment updatesAction: Re-evaluate pipeline risk-adjusted NPV and adjust long-term growth projections.
Research as of 19 Jun 2026